Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1/2 6Phase 1 6Phase NA 1Phase EARLY_PHASE1 1

Status

Recruiting 5Completed 1Active not recruiting 1

Sponsor Class

OTHER 5INDUSTRY 1FED 1

Study Type

Interventional 7

Sponsor

Cancer Type

Lymphoid 7Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 95Leukemia, Lymphocytic, Chronic, B-Cell 46Lymphoma, Mantle-Cell 16Myelodysplastic Syndromes 15Leukemia 13Leukemia, Biphenotypic, Acute 10Recurrence 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 9Neoplasms 9Lymphoma, B-Cell, Marginal Zone 8Waldenstrom Macroglobulinemia 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma 7Leukemia, Myelomonocytic, Chronic 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Multiple Myeloma 6Lymphoma, Follicular 6Myeloproliferative Disorders 5Lymphoma, Large B-Cell, Diffuse 5Burkitt Lymphoma 5Neoplasm, Residual 4Leukemia, B-Cell 3Chromosome 17 deletion 3Blastic Plasmacytoid Dendritic Cell Neoplasm 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoproliferative Disorders 2Lymphoma, T-Cell 2Lymphoma, Non-Hodgkin 2Leukemia, Monocytic, Acute 2Hematologic Neoplasms 2

Interventions

Cyclophosphamide 241Rituximab 223Etoposide 138Filgrastim 113Vincristine 112Doxorubicin 104Prednisone 90Cytarabine 90Methotrexate 79fludarabine phosphate 77Radiotherapy 76Peripheral Blood Stem Cell Transplantation 71Melphalan 71Busulfan 60Tacrolimus 48Dexamethasone 48Mycophenolic Acid 46Carmustine 46Granulocyte Colony-Stimulating Factor 44fludarabine 43Antilymphocyte Serum 40Ifosfamide 38sargramostim 34Whole-Body Irradiation 34Cyclosporine 33Bortezomib 32Gemcitabine 30Methylprednisolone 27Bendamustine Hydrochloride 27Lenalidomide 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma × venetoclax × Clear all
NCT05951959 2026-06-01

TrAVeRse

AstraZeneca

Phase 2 Active not recruiting
108 enrolled
Lymphoid

Lymphoma, Lymphoma, Mantle-Cell

NCT05099471 2026-05-05

VIWA-1

University of Ulm

Phase 2 Recruiting
80 enrolled
Lymphoid

Lymphoma, Waldenstrom Macroglobulinemia, Neoplasms

NCT06510309 2026-03-13

Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma

Beth Israel Deaconess Medical Center

Phase 2 Recruiting
33 enrolled
Lymphoid

Lymphoma, Lymphoma, B-Cell, Marginal Zone

NCT06712121 2026-02-02

Venetoclax and Decitabine in R/R T-ALL

Seoul National University Hospital

Phase 2 Recruiting
28 enrolled
Lymphoid

Lymphoma

NCT06520098 2025-10-14

Benefit VA

VA Office of Research and Development

Phase 2 Recruiting
100 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT06742463 2024-12-19

VHAG in Treating R/R T-ALL/LBL

First Affiliated Hospital of Zhejiang University

Phase 2 Recruiting
50 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03276468 2023-01-10

Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas

The Lymphoma Academic Research Organisation

Phase 2 Completed
136 enrolled
Lymphoid

Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡